Marta Chiaravalli

798 total citations
19 papers, 554 citations indexed

About

Marta Chiaravalli is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marta Chiaravalli has authored 19 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marta Chiaravalli's work include Pancreatic and Hepatic Oncology Research (16 papers), Cancer Genomics and Diagnostics (11 papers) and Renal cell carcinoma treatment (9 papers). Marta Chiaravalli is often cited by papers focused on Pancreatic and Hepatic Oncology Research (16 papers), Cancer Genomics and Diagnostics (11 papers) and Renal cell carcinoma treatment (9 papers). Marta Chiaravalli collaborates with scholars based in Italy, Canada and France. Marta Chiaravalli's co-authors include Michele Reni, Eileen M. O’Reilly, Silvia Zanon, Luca Gianni, Gianpaolo Balzano, Claudio Doglioni, Massimo Falconi, Paolo Giorgio Arcidiacono, Chiara Pircher and Domenica Ceraulo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Marta Chiaravalli

15 papers receiving 552 citations

Peers

Marta Chiaravalli
Karin Rita Tamas Switzerland
Paul A. Toste United States
Toshiro Ogura Japan
Hanguang Hu China
Stephan B. Dreyer United Kingdom
Marina Macchini Italy
Y Matsuyama Japan
Adelaida La Casta Spain
Clara Fugazza Italy
N. Vardakis Greece
Karin Rita Tamas Switzerland
Marta Chiaravalli
Citations per year, relative to Marta Chiaravalli Marta Chiaravalli (= 1×) peers Karin Rita Tamas

Countries citing papers authored by Marta Chiaravalli

Since Specialization
Citations

This map shows the geographic impact of Marta Chiaravalli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Chiaravalli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Chiaravalli more than expected).

Fields of papers citing papers by Marta Chiaravalli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Chiaravalli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Chiaravalli. The network helps show where Marta Chiaravalli may publish in the future.

Co-authorship network of co-authors of Marta Chiaravalli

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Chiaravalli. A scholar is included among the top collaborators of Marta Chiaravalli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Chiaravalli. Marta Chiaravalli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Chiaravalli, Marta, Cinzia Bagalá, Maria Bensi, et al.. (2024). Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. The Lancet Oncology. 25(12). 1655–1665. 12 indexed citations
3.
Chiaravalli, Marta, Anthony Turpin, Florian Castet, et al.. (2023). Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. SHILAP Revista de lepidopterología. 2. 100011–100011.
4.
Nichetti, Federico, Mario Domenico Rizzato, Maria Bensi, et al.. (2023). P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers. Annals of Oncology. 34. S113–S113.
5.
Bensi, Maria, Lisa Salvatore, Jacopo Lenkowicz, et al.. (2023). Epidemiological and clinicopathological features of patients (pts) with early- (EOPC) and late-onset pancreatic cancer (LOPC): A mono-institutional retrospective analysis.. Journal of Clinical Oncology. 41(16_suppl). 10533–10533. 1 indexed citations
6.
Chiaravalli, Marta, et al.. (2022). Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers. Cells. 11(19). 3033–3033. 34 indexed citations
7.
Chiaravalli, Marta, et al.. (2022). The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study.. Journal of Clinical Oncology. 40(16_suppl). e16180–e16180. 1 indexed citations
8.
9.
Macchini, Marina, Marta Chiaravalli, Chiara Pircher, et al.. (2020). Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease. 53(1). 117–121. 1 indexed citations
10.
Chiaravalli, Marta, Geny Piro, Lisa Salvatore, et al.. (2020). Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. International Journal of Molecular Sciences. 21(17). 6386–6386. 13 indexed citations
11.
Reni, Michele, Gianpaolo Balzano, Silvia Zanon, et al.. (2018). Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. ˜The œLancet. Gastroenterology & hepatology. 3(6). 413–423. 166 indexed citations
12.
Reni, Michele, Silvia Zanon, Umberto Peretti, et al.. (2018). Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. ˜The œLancet. Gastroenterology & hepatology. 3(10). 691–697. 54 indexed citations
13.
Reni, Michele, Silvia Zanon, Gianpaolo Balzano, et al.. (2018). A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer. 102. 95–102. 42 indexed citations
14.
Macchini, Marina, Marta Chiaravalli, Silvia Zanon, et al.. (2018). Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treatment Reviews. 72. 1–6. 42 indexed citations
15.
Reni, Michele, Silvia Zanon, Gianpaolo Balzano, et al.. (2017). Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Annals of Oncology. 28(11). 2786–2792. 73 indexed citations
16.
Chiaravalli, Marta, Michele Reni, & Eileen M. O’Reilly. (2017). Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews. 60. 32–43. 109 indexed citations
17.
Reni, Michele, Silvia Zanon, Chiara Pircher, et al.. (2017). Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma. Annals of Oncology. 28. v252–v252. 2 indexed citations
18.
Reni, Michele, Silvia Zanon, Gianpaolo Balzano, et al.. (2016). Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma. Annals of Oncology. 27. vi230–vi230. 3 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karin Rita Tamas Breakdown of academic impact, for papers by Paul A. Toste Breakdown of academic impact, for papers by Toshiro Ogura Breakdown of academic impact, for papers by Hanguang Hu Breakdown of academic impact, for papers by Stephan B. Dreyer Breakdown of academic impact, for papers by Marina Macchini Breakdown of academic impact, for papers by Y Matsuyama Breakdown of academic impact, for papers by Adelaida La Casta Breakdown of academic impact, for papers by Clara Fugazza Breakdown of academic impact, for papers by N. Vardakis
Rankless by CCL
2026